Rocket Pharmaceuticals, Inc. Common Stock
RCKTRocket Pharmaceuticals, Inc. is a clinical-stage company focused on developing innovative gene therapies for rare pediatric diseases. Founded in 2015 and based in New York, the company leverages its platform to develop treatments aimed at addressing the underlying genetic causes of severe, often life-threatening conditions in children. Rocket Pharmaceuticals emphasizes a multidisciplinary approach, combining gene therapy, gene editing, and cellular therapy technologies to deliver potential cures for rare disorders.
Company News
Law firm investigating Rocket Pharmaceuticals for potential securities fraud related to undisclosed clinical trial protocol changes and serious adverse events in RP-A501 study, which led to a 37% stock price drop.
Law firm alerts investors about potential securities fraud class action lawsuits for four companies, alleging misleading statements and undisclosed risks during specific class periods in 2024-2025.
Rosen Law Firm alerts Rocket Pharmaceuticals investors about a securities class action lawsuit alleging false statements regarding the effectiveness and safety of drug candidate RP-A501, with an important deadline on August 11, 2025.
Law Offices of Frank R. Cruz alerts investors about an upcoming August 11, 2025 deadline to participate in a securities fraud class action lawsuit against Rocket Pharmaceuticals following an FDA clinical hold on a Danon disease treatment trial after a patient's death.
Rocket Pharmaceuticals faces a class action lawsuit alleging misleading statements about its Phase 2 clinical trial for RP-A501, with claims of concealing serious adverse events including patient death, which led to an FDA clinical hold and stock price decline.
